EDAP Edap Tms S.A. ADS

EDAP TMS SA to Announce Third Quarter 2022 Financial Results on Wednesday, November 16th, 2022

EDAP TMS SA to Announce Third Quarter 2022 Financial Results on Wednesday, November 16th, 2022

Company to host conference call and webcast on Thursday, November 17th at 8:30 am EDT

LYON, France, November 2, 2022 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30th after the markets close on Wednesday, November 16th, 2022.

An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of EDAP U.S., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Thursday, November 17th, 2022. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Call & Webcast

Thursday, November 17th @ 8:30am Eastern Time

Domestic:        877-451-6152

International:   201-389-0879

Passcode:        13733576

Webcast:        

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit -tms.com, us.hifu-prostate.com and

Company contact:

Blandine Confort

Investor Relations / Legal Affairs

EDAP TMS SA

50

Investor Contact

John Fraunces

LifeSci Advisors, LLC

212-915-2568



EN
02/11/2022

Underlying

EDAPEdap Tms S.A. ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Edap Tms S.A. ADS

 PRESS RELEASE
Free
EDAP Edap Tms S.A. A...

EDAP Reports First Quarter 2025 Financial Results

EDAP Reports First Quarter 2025 Financial Results           Achieved a Record Number of Focal One® Robotic HIFU System Placements for a First Quarter Period Received CE Mark Designation for Focal One for the Treatment of Deep Infiltrating Endometriosis Positive Final Results of FARP Randomized Controlled Trial Presented at American Urology Association Annual Meeting (AUA 2025)Launched the New Focal One i Robotic HIFU System Performed World’s First Remote Transcontinental Focal One Robotic HIFU Procedure Successfully AUSTIN, Texas, May 15, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global lea...

May 15, 2025 1 EN
 PRESS RELEASE
Free
EDAP Edap Tms S.A. A...

EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025

EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025 Company to host conference call and webcast on Thursday, May 15th at 8:30am EDT LYON, France, May 1, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2025, before the markets open on Thursday, May 15th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, ...

May 1, 2025 1 EN
 PRESS RELEASE
Free
EDAP Edap Tms S.A. A...

EDAP Announces Positive Results from the FARP Randomized Controlled Tr...

EDAP Announces Positive Results from the FARP Randomized Controlled Trial Presented at the American Urological Association (AUA) Annual Meeting Final 3-year outcome of Focal Ablation versus Radical Prostatectomy (FARP) Randomized Controlled Trial (RCT) presented at 120th AUA Annual Meeting on Sunday, April 27, 2025. Study achieved its primary endpoint and demonstrated that the rate of treatment failure in the Focal Ablation (FA) group is non-inferior to that in the Radical Prostatectomy (RP) group at the final 36-month follow-up. AUSTIN, Texas, April 29, 2025 - EDAP TMS SA (Nasdaq: EDAP), ...

April 29, 2025 1 EN
 PRESS RELEASE
Free
EDAP Edap Tms S.A. A...

EDAP To Launch New Focal One® i Robotic HIFU system at the Upcoming 12...

EDAP To Launch New Focal One® i Robotic HIFU system at the Upcoming 120th American Urological Association (AUA) Annual Meeting Focal One i expands HIFUsion® patient-specific imaging compatibility to include PSMA PET, ExactVu™ Micro-Ultrasound, along with AI-driven and intelligent algorithms including Unfold AI™ and OnQ™ ProstateFocal One i extends HIFUsion capabilities to integrate Koelis® 3D biopsy maps and DynaCAD Urology datasetsFocal One i system will enable future capabilities including treatment streaming and recording, remote collaborative procedures and expanded clinical indications...

April 24, 2025 1 EN
 PRESS RELEASE
Free
EDAP Edap Tms S.A. A...

EDAP Announces Significant Presence of Focal One® at the Upcoming 120t...

EDAP Announces Significant Presence of Focal One® at the Upcoming 120th American Urological Association (AUA) Annual Meeting Activities to include expert-led demonstrations, semi-live Focal One procedures and hands-on simulations Final results of randomized clinical trial (FARP Study) comparing ultrasound-based focal ablation versus radical prostatectomy as a first-line treatment for prostate cancer Presentation on the first ever remote transatlantic Focal One Robotic HIFU procedure will be given by Ruben Olivares, MD, Urologic Surgeon at the Cleveland Clinic, at the AUA session of the Engi...

April 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch